{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T19:08:38Z","timestamp":1795028918267,"version":"4.10.2"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,2]],"date-time":"2019-01-02T00:00:00Z","timestamp":1546387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,1,2]],"date-time":"2019-01-02T00:00:00Z","timestamp":1546387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Myofibroblasts are the key effector cells responsible for excessive extracellular matrix deposition in multiple fibrotic conditions, including idiopathic pulmonary fibrosis (IPF). The PI3K\/Akt\/mTOR axis has been implicated in fibrosis, with pan-PI3K\/mTOR inhibition currently under clinical evaluation in IPF. Here we demonstrate that rapamycin-insensitive mTORC1 signaling via 4E-BP1 is a critical pathway for TGF-\u03b2<jats:sub>1<\/jats:sub> stimulated collagen synthesis in human lung fibroblasts, whereas canonical PI3K\/Akt signaling is not required. The importance of mTORC1 signaling was confirmed by CRISPR-Cas9 gene editing in normal and IPF fibroblasts, as well as in lung cancer-associated fibroblasts, dermal fibroblasts and hepatic stellate cells. The inhibitory effect of ATP-competitive mTOR inhibition extended to other matrisome proteins implicated in the development of fibrosis and human disease relevance was demonstrated in live precision-cut IPF lung slices. Our data demonstrate that the mTORC1\/4E-BP1 axis represents a critical signaling node during fibrogenesis with potential implications for the development of novel anti-fibrotic strategies.<\/jats:p>","DOI":"10.1038\/s41467-018-07858-8","type":"journal-article","created":{"date-parts":[[2018,12,27]],"date-time":"2018-12-27T17:57:52Z","timestamp":1545933472000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":213,"title":["The mTORC1\/4E-BP1 axis represents a critical signaling node during fibrogenesis"],"prefix":"10.1038","volume":"10","author":[{"given":"Hannah V.","family":"Woodcock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica D.","family":"Eley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Guillotin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9957-0681","authenticated-orcid":false,"given":"Manuela","family":"Plat\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmel B.","family":"Nanthakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Martufi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Peace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Joberty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Poeckel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert B.","family":"Good","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam R.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nico","family":"Zinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Redding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen J.","family":"Forty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2170-8791","authenticated-orcid":false,"given":"Robert E.","family":"Hynds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Swanton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Karsdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toby M.","family":"Maher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Bergamini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard P.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy D.","family":"Blanchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul F.","family":"Mercer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1370-9417","authenticated-orcid":false,"given":"Rachel C.","family":"Chambers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,2]]},"reference":[{"key":"7858_CR1","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/nrc.2016.73","volume":"16","author":"R Kalluri","year":"2016","unstructured":"Kalluri, R. The biology and function of fibroblasts in cancer. Nat. Rev. Cancer 16, 582\u2013598 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"7858_CR2","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1056\/NEJMra1300575","volume":"372","author":"DC Rockey","year":"2015","unstructured":"Rockey, D. C., Bell, P. D. & Hill, J. A. Fibrosis\u2014a common pathway to organ injury and failure. N. Engl. J. Med. 372, 1138\u20131149 (2015).","journal-title":"N. Engl. J. Med."},{"key":"7858_CR3","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/JTO.0b013e3181f8a1bd","volume":"6","author":"RM Bremnes","year":"2011","unstructured":"Bremnes, R. M. et al. The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer. J. Thorac. Oncol. 6, 209\u2013217 (2011).","journal-title":"J. Thorac. Oncol."},{"key":"7858_CR4","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","volume":"370","author":"TE King","year":"2014","unstructured":"King, T. E. et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 370, 2083\u20132092 (2014).","journal-title":"N. Engl. J. Med."},{"key":"7858_CR5","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","volume":"370","author":"L Richeldi","year":"2014","unstructured":"Richeldi, L. et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N. Engl. J. Med. 370, 2071\u20132082 (2014).","journal-title":"N. Engl. J. Med."},{"key":"7858_CR6","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/nrd.2017.170","volume":"16","author":"AL Mora","year":"2017","unstructured":"Mora, A. L., Rojas, M., Pardo, A. & Selman, M. Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease. Nat. Rev. Drug Discov. 16, 755\u2013772 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"7858_CR7","doi-asserted-by":"crossref","first-page":"L1164","DOI":"10.1152\/ajplung.00220.2017","volume":"313","author":"D \u00c1lvarez","year":"2017","unstructured":"\u00c1lvarez, D. et al. IPF lung fibroblasts have a senescent phenotype. Am. J. Physiol. Cell Mol. Physiol. 313, L1164\u2013L1173 (2017).","journal-title":"Am. J. Physiol. Cell. Mol. Physiol."},{"key":"7858_CR8","doi-asserted-by":"publisher","unstructured":"Yang, I. V. & Schwartz, D. A. Epigenetics of idiopathic pulmonary fibrosis. Transl. Res. https:\/\/doi.org\/10.1016\/j.trsl.2014.03.011 (2014).","DOI":"10.1016\/j.trsl.2014.03.011"},{"key":"7858_CR9","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.retram.2016.09.003","volume":"64","author":"B Hinz","year":"2016","unstructured":"Hinz, B. The role of myofibroblasts in wound healing. Curr. Res. Transl. Med. 64, 171\u2013177 (2016).","journal-title":"Curr. Res. Transl. Med."},{"key":"7858_CR10","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1378\/chest.06-2568","volume":"132","author":"CJ Scotton","year":"2007","unstructured":"Scotton, C. J. & Chambers, R. C. Molecular targets in pulmonary fibrosis. Chest 132, 1311\u20131321 (2007).","journal-title":"Chest"},{"key":"7858_CR11","first-page":"1257","volume":"138","author":"C Kuhn","year":"1991","unstructured":"Kuhn, C. & McDonald, J. A. The roles of the myofibroblast in idiopathic pulmonary fibrosis. Ultrastructural and immunohistochemical features of sites of active extracellular matrix synthesis. Am. J. Pathol. 138, 1257\u20131265 (1991).","journal-title":"Am. J. Pathol."},{"key":"7858_CR12","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1136\/gut.2005.082701","volume":"55","author":"E Novo","year":"2006","unstructured":"Novo, E. et al. Overexpression of Bcl-2 by activated human hepatic stellate cells: resistance to apoptosis as a mechanism of progressive hepatic fibrogenesis in humans. Gut 55, 1174\u20131182 (2006).","journal-title":"Gut"},{"key":"7858_CR13","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1002\/1529-0131(200107)44:7<1667::AID-ART291>3.0.CO;2-Y","volume":"44","author":"B Santiago","year":"2001","unstructured":"Santiago, B., Galindo, M., Rivero, M. & Pablos, J. L. Decreased susceptibility to Fas-induced apoptosis of systemic sclerosis dermal fibroblasts. Arthritis Rheum. 44, 1667\u20131676 (2001).","journal-title":"Arthritis Rheum."},{"key":"7858_CR14","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1513\/pats.201201-011AW","volume":"9","author":"SH Phan","year":"2012","unstructured":"Phan, S. H. Genesis of the myofibroblast in lung injury and fibrosis. Proc. Am. Thorac. Soc. 9, 148\u2013152 (2012).","journal-title":"Proc. Am. Thorac. Soc."},{"key":"7858_CR15","doi-asserted-by":"crossref","first-page":"a022293","DOI":"10.1101\/cshperspect.a022293","volume":"10","author":"KK Kim","year":"2018","unstructured":"Kim, K. K., Sheppard, D. & Chapman, H. A. TGF-\u03b21 signaling and tissue fibrosis. Cold Spring Harb. Perspect. Biol. 10, a022293 (2018).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"7858_CR16","doi-asserted-by":"crossref","first-page":"a022301","DOI":"10.1101\/cshperspect.a022301","volume":"9","author":"RJ Akhurst","year":"2017","unstructured":"Akhurst, R. J. Targeting TGF-\u03b2 signaling for therapeutic gain. Cold Spring Harb. Perspect. Biol. 9, a022301 (2017).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"7858_CR17","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/nrg1879","volume":"7","author":"JA Engelman","year":"2006","unstructured":"Engelman, J. A., Luo, J. & Cantley, L. C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 7, 606\u2013619 (2006).","journal-title":"Nat. Rev. Genet."},{"key":"7858_CR18","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","volume":"149","author":"M Laplante","year":"2012","unstructured":"Laplante, M. & Sabatini, D. mTOR signaling in growth control and disease. Cell 149, 274\u2013293 (2012).","journal-title":"Cell"},{"key":"7858_CR19","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1042\/BJ20080281","volume":"412","author":"J Huang","year":"2008","unstructured":"Huang, J. & Manning, B. D. The TSC1\u2013TSC2 complex: a molecular switchboard controlling cell growth. Biochem. J. 412, 179\u2013190 (2008).","journal-title":"Biochem. J."},{"key":"7858_CR20","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1164\/rccm.200507-1058OC","volume":"173","author":"ES White","year":"2006","unstructured":"White, E. S. et al. Negative regulation of myofibroblast differentiation by PTEN (phosphatase and tensin homolog deleted on chromosome 10). Am. J. Respir. Crit. Care Med. 173, 112\u2013121 (2006).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"7858_CR21","doi-asserted-by":"crossref","unstructured":"Xia, H. et al. Pathological integrin signaling enhances proliferation of primary lung fibroblasts from patients with idiopathic pulmonary fibrosis. J. Exp. Med. 205, 1659\u20131672 (2008).","DOI":"10.1084\/jem.20080001"},{"key":"7858_CR22","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1136\/thoraxjnl-2015-207429","volume":"71","author":"PF Mercer","year":"2016","unstructured":"Mercer, P. F. et al. Exploration of a potent PI3 kinase\/mTOR inhibitor as a novel anti-fibrotic agent in IPF. Thorax 71, 701\u2013711 (2016).","journal-title":"Thorax"},{"key":"7858_CR23","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1200\/JCO.2011.36.1360","volume":"30","author":"JC Bendell","year":"2012","unstructured":"Bendell, J. C. et al. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 30, 282\u2013290 (2012).","journal-title":"J. Clin. Oncol."},{"key":"7858_CR24","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/nrd4204","volume":"13","author":"DA Fruman","year":"2014","unstructured":"Fruman, D. A. & Rommel, C. PI3K and cancer: lessons, challenges and opportunities. Nat. Rev. Drug Discov. 13, 140\u2013156 (2014).","journal-title":"Nat. Rev. Drug Discov."},{"key":"7858_CR25","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/bjc.2016.430","volume":"116","author":"PE Heudel","year":"2017","unstructured":"Heudel, P.-E. et al. Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I-type II study from the GINECO group. Br. J. Cancer 116, 303\u2013309 (2017).","journal-title":"Br. J. Cancer"},{"key":"7858_CR26","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Mart\u00ednez, J. M. & Alessi, D. R. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). Biochem. J. 416, 375\u2013385 (2008).","DOI":"10.1042\/BJ20081668"},{"key":"7858_CR27","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1111\/j.1476-5381.2009.00387.x","volume":"158","author":"CZC Chen","year":"2009","unstructured":"Chen, C. Z. C. et al. The Scar-in-a-Jar: studying potential antifibrotic compounds from the epigenetic to extracellular level in a single well. Br. J. Pharmacol. 158, 1196\u20131209 (2009).","journal-title":"Br. J. Pharmacol."},{"key":"7858_CR28","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1101\/gad.912401","volume":"15","author":"AC Gingras","year":"2001","unstructured":"Gingras, A. C. et al. Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev. 15, 2852\u20132864 (2001).","journal-title":"Genes Dev."},{"key":"7858_CR29","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nature11083","volume":"485","author":"CC Thoreen","year":"2012","unstructured":"Thoreen, C. C. et al. A unifying model for mTORC1-mediated regulation of mRNA translation. Nature 485, 109\u2013113 (2012).","journal-title":"Nature"},{"key":"7858_CR30","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.addr.2015.07.007","volume":"99","author":"G Ishii","year":"2016","unstructured":"Ishii, G., Ochiai, A. & Neri, S. Phenotypic and functional heterogeneity of cancer-associated fibroblast within the tumor microenvironment. Adv. Drug Deliv. Rev. 99, 186\u2013196 (2016).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"7858_CR31","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.cellsig.2006.10.001","volume":"19","author":"JC Horowitz","year":"2007","unstructured":"Horowitz, J. C. et al. Combinatorial activation of FAK and AKT by transforming growth factor-beta1 confers an anoikis-resistant phenotype to myofibroblasts. Cell Signal. 19, 761\u2013771 (2007).","journal-title":"Cell Signal."},{"key":"7858_CR32","doi-asserted-by":"crossref","unstructured":"Horowitz, J. C. et al. Activation of the pro-survival phosphatidylinositol 3-kinase\/AKT pathway by transforming growth factor-beta1 in mesenchymal cells is mediated by p38 MAPK-dependent induction of an autocrine growth factor. J. Biol. Chem. 279, 1359\u20131367 (2004).","DOI":"10.1074\/jbc.M306248200"},{"key":"7858_CR33","doi-asserted-by":"crossref","first-page":"e24663","DOI":"10.1371\/journal.pone.0024663","volume":"6","author":"E Conte","year":"2011","unstructured":"Conte, E. et al. Inhibition of PI3K prevents the proliferation and differentiation of human lung fibroblasts into myofibroblasts: the role of class I P110 isoforms. PLoS ONE 6, e24663 (2011).","journal-title":"PLoS One"},{"key":"7858_CR34","doi-asserted-by":"crossref","unstructured":"Ricupero, D. A. et al. Phosphatidylinositol 3-kinase-dependent stabilization of \u03b11(I) collagen mRNA in human lung fibroblasts. Am. J. Physiol. Cell Physiol. 281, C99\u2013C105 (2001).","DOI":"10.1152\/ajpcell.2001.281.1.C99"},{"key":"7858_CR35","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1074\/jbc.M310412200","volume":"279","author":"CE Runyan","year":"2004","unstructured":"Runyan, C. E., Schnaper, H. W. & Poncelet, A.-C. The phosphatidylinositol 3-kinase\/Akt pathway enhances Smad3-stimulated mesangial cell collagen I expression in response to transforming growth factor-\u03b21. J. Biol. Chem. 279, 2632\u20132639 (2004).","journal-title":"J. Biol. Chem."},{"key":"7858_CR36","doi-asserted-by":"publisher","unstructured":"Cleary, J. M. & Shapiro, G. I. Development of phosphoinositide-3 kinase pathway inhibitors for advanced cancer. Curr. Oncol. Rep. 12, https:\/\/doi.org\/10.1007\/s11912-010-0091-6 (2010).","DOI":"10.1007\/s11912-010-0091-6"},{"key":"7858_CR37","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","volume":"168","author":"RA Saxton","year":"2017","unstructured":"Saxton, R. A. & Sabatini, D. M. mTOR signaling in growth, metabolism, and disease. Cell 168, 960\u2013976 (2017).","journal-title":"Cell"},{"key":"7858_CR38","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.tibs.2011.03.006","volume":"36","author":"MC Mendoza","year":"2011","unstructured":"Mendoza, M. C., Er, E. E. & Blenis, J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem. Sci. 36, 320\u2013328 (2011).","journal-title":"Trends Biochem. Sci."},{"key":"7858_CR39","doi-asserted-by":"crossref","first-page":"e106155","DOI":"10.1371\/journal.pone.0106155","volume":"9","author":"W Chang","year":"2014","unstructured":"Chang, W. et al. A critical role for the mTORC2 pathway in lung fibrosis. PLoS ONE 9, e106155 (2014).","journal-title":"PLoS ONE"},{"key":"7858_CR40","doi-asserted-by":"crossref","first-page":"6262","DOI":"10.1074\/jbc.M115.672170","volume":"291","author":"NM Walker","year":"2016","unstructured":"Walker, N. M. et al. Mechanistic target of rapamycin complex 1 (mTORC1) and mTORC2 as key signaling intermediates in mesenchymal cell activation. J. Biol. Chem. 291, 6262\u20136271 (2016).","journal-title":"J. Biol. Chem."},{"key":"7858_CR41","doi-asserted-by":"crossref","first-page":"1236566","DOI":"10.1126\/science.1236566","volume":"341","author":"SA Kang","year":"2013","unstructured":"Kang, S. A. et al. mTORC1 phosphorylation sites encode their sensitivity to starvation and rapamycin. Science 341, 1236566 (2013).","journal-title":"Science"},{"key":"7858_CR42","doi-asserted-by":"crossref","first-page":"17058","DOI":"10.1074\/jbc.M100754200","volume":"276","author":"F Verrecchia","year":"2001","unstructured":"Verrecchia, F., Chu, M. L. & Mauviel, A. Identification of novel TGF-beta\/Smad gene targets in dermal fibroblasts using a combined cDNA microarray\/promoter transactivation approach. J. Biol. Chem. 276, 17058\u201317062 (2001).","journal-title":"J. Biol. Chem."},{"key":"7858_CR43","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.4049\/jimmunol.173.3.2099","volume":"173","author":"P Bonniaud","year":"2004","unstructured":"Bonniaud, P. et al. Smad3 null mice develop airspace enlargement and are resistant to TGF-beta-mediated pulmonary fibrosis. J. Immunol. 173, 2099\u20132108 (2004).","journal-title":"J. Immunol."},{"key":"7858_CR44","doi-asserted-by":"crossref","unstructured":"Xie, J., Wang, X. & Proud, C. G. mTOR inhibitors in cancer therapy. F1000Res. 5, 2078 (2016).","DOI":"10.12688\/f1000research.9207.1"},{"key":"7858_CR45","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/j.1440-1843.2011.01955.x","volume":"16","author":"MA Malouf","year":"2011","unstructured":"Malouf, M. A., Hopkins, P., Snell, G. & Glanville, A. R. An investigator-driven study of everolimus in surgical lung biopsy confirmed idiopathic pulmonary fibrosis. Respirology 16, 776\u2013783 (2011).","journal-title":"Respirology"},{"key":"7858_CR46","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1165\/rcmb.2017-0096ST","volume":"56","author":"RG Jenkins","year":"2017","unstructured":"Jenkins, R. G. et al. An Official American Thoracic Society Workshop Report: use of animal models for the preclinical assessment of potential therapies for pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 56, 667\u2013679 (2017).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"7858_CR47","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1038\/nm.3282","volume":"19","author":"NC Henderson","year":"2013","unstructured":"Henderson, N. C. et al. Targeting of \u03b1v integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat. Med. 19, 1617\u20131624 (2013).","journal-title":"Nat. Med."},{"key":"7858_CR48","doi-asserted-by":"crossref","first-page":"D447","DOI":"10.1093\/nar\/gkv1145","volume":"44","author":"JA Vizca\u00edno","year":"2016","unstructured":"Vizca\u00edno, J. A. et al. 2016 update of the PRIDE database and its related tools. Nucleic Acids Res. 44, D447\u2013D456 (2016).","journal-title":"Nucleic Acids Res."},{"key":"7858_CR49","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.clinbiochem.2010.07.025","volume":"43","author":"DJ Leeming","year":"2010","unstructured":"Leeming, D. J. et al. Enzyme-linked immunosorbent serum assays (ELISAs) for rat and human N-terminal pro-peptide of collagen type I (PINP)\u2014assessment of corresponding epitopes. Clin. Biochem. 43, 1249\u20131256 (2010).","journal-title":"Clin. Biochem."}],"updated-by":[{"DOI":"10.1038\/s41467-020-18621-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T00:00:00Z","timestamp":1599782400000}}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-07858-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-07858-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-07858-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T18:29:46Z","timestamp":1671215386000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-07858-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,2]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["7858"],"URL":"https:\/\/doi.org\/10.1038\/s41467-018-07858-8","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41467-020-18621-3","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,2]]},"assertion":[{"value":"20 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2020","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"An amendment to this paper has been published and can be accessed via a link at the top of the paper.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This work was part-funded by a collaborative framework agreement awarded to R.C.C. by GlaxoSmithKline. In terms of potential conflict of interest, the following authors: C.B.N., M.M., S.P., G.J., D.P., R.B.G., A.R.T., G.B., A.D.B., N.Z., and R.P.M. were employees of GlaxoSmithKline which has R&D programs for IPF at the time of writing. M.K. is an employee of Nordic Biosciences with a commercial interest in proprietary assay development for biomarker discovery. T.M.M. has no declarations directly related to this manuscript. He has, however, received industry-academic research funding from GlaxoSmithKline R&D, UCB, and Novartis and has received consultancy or speakers fees from Pellis, Astra Zeneca, Bayer, Biogen Idec, Boehringer Ingelheim, Cipla, Galapagos, GlaxoSmithKline R&D, ProMetic, Roche (and previously InterMune), Sanofi-Aventis, and UCB. A.J.F. has no declarations directly related to this manuscript. His institution has received industry-academic research funding from GlaxoSmithKline R&D, Genentech, Pfizer and Nuformix. His institution has received consultancy fees from Mallinckrodt Pharmaceuticals. All remaining authors declare no competing interests. All data presented have been recorded in full compliance with GSK data integrity.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6"}}